MSMinako Sugiyama

Minako Sugiyama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Minako Sugiyama has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Safety and Efficacy of Vinorelbine and Continuous Low‐Dose Cyclophosphamide Chemotherapy in Japanese Pediatric Patients With Relapsed or Refractory Rhabdomyosarcoma

    by Risa Yanai, Minako Sugiyama, Bunpei Miyazaki, Natsumi Kikuchi, Kosuke Tamefusa, Kayoko Tao, Eriko Uchida, Kiyotaka Isobe, Kan Yonemori, Ayumu Arakawa

    Background: Relapsed or refractory rhabdomyosarcoma (RMS) has a poor prognosis, and optimal treatment remains an unmet need. Vinorelbine (VNR) and low‐dose metronomic cyclophosphamide (CPM) have shown clinical efficacy and are used as maintenance therapy in localized and metastatic disease; however, dose reductions are frequently required due to myelosuppression. This study evaluated the safety, efficacy, and optimal dosing of VNR and CPM in pediatric patients with relapsed or refractory RMS. Methods: Pediatric patients treated with VNR and CPM at our institution between March 2014 and May 2024 were retrospectively reviewed. Dosing was based on the RMS 2005 protocol, with dose reductions implemented before or during treatment to minimize treatment interruptions. Results: Eighteen patients received 139 cycles of therapy (median age at initiation, 15.6 years; range, 7–21 years), including 13 relapsed and 5 refractory cases. The median number of cycles administered was 5.5 (range, 1–26), with a median interval of 28 days. The median adjusted dose ratios over three cycles were 55% for VNR and 53.5% for CPM. Disease control lasting longer than 10 months was achieved in six patients (33%). Neutropenia occurred in 89% of patients, whereas anemia and thrombocytopenia requiring transfusion occurred in 28% and 22%, respectively. No grade 4 non‐hematologic toxicities or treatment‐related deaths were observed after dose adjustment. Conclusions: VNR and continuous low‐dose CPM chemotherapy were safe and feasible with dose adjustments. In heavily pretreated patients, initiating therapy at approximately 80% of the standard dose may be appropriate.

  • Open Access

    Observation of notable therapeutic response in a patient with systemic juvenile xanthogranuloma with KIF5B-ALK fusion

    by Minako Sugiyama, Shinsuke Hirabayashi, Yukitomo Ishi, Junko Kikuchi, Ayako Ishikura, Hiroaki Motegi, Yuki Ueda, Saori Sawai, Kazuya Hara, Yukayo Terashita, et al.

    We report the case of a 1-year-old male patient with systemic juvenile xanthogranuloma in whom central nervous system lesions caused developmental retardation, spasticity and clonus of the lower extremities. He needed tube feeding and experienced severe bronchitis and generalised convulsive seizure. KIF5B-ALK fusion was identified in the cutaneous lesion, and he was administered alectinib, an ALK inhibitor. Two months after the initiation of alectinib administration, the central nervous system lesions achieved partial regression. The spasticity and clonus were also relieved. A high index of cognition is needed for ALK fusion in infants with histiocytosis.

  • Open Access

    The heterozygous NUDT15 variant is not associated with the severity of 6-mercaptopurine-related side effects in early intensification therapy for childhood acute lymphoblastic leukemia

    by Jimei Zhao, Masahiro Ueki, Saori Sawai, Minako Sugiyama, Yukayo Terashita, Shinsuke Hirabayashi, Yuko Cho, Ryoji Kobayashi, Yoichi Tanaka, Atsushi Manabe


  • Long-term consequences of residual lesions after chemoradiotherapy in patients with germinoma at onset.

    by Shigeru Yamaguchi, Michinari Okamoto, Yukitomo Ishi, Ryosuke Sawaya, Hiroaki Motegi, Minako Sugiyama, Taisuke Harada, Noriyuki Fujima, Takashi Mori, Takayuki Hashimoto, et al.

    In patients with intracranial germ cell tumors, residual lesions are sometimes observed after completion of primary chemoradiotherapy. Although salvage resection of these end-of-treatment residual lesions is recommended for patients with nongerminomatous germ cell tumors, the necessity of early salvage resection for those with germinoma is not clear. The aim of this study was to investigate the frequency of residual germinoma lesions after primary chemoradiotherapy, as well as their management, long-term consequences, and prognosis. The authors retrospectively reviewed patients who were primarily treated for germinoma between 2002 and 2021. Residual lesions were evaluated with MRI with and without contrast enhancement within 2 weeks after chemoradiotherapy. The decision to perform salvage resection of residual lesions was at the discretion of the treating physicians. The change in appearance of residual lesions was assessed with serial MRI. Overall survival (OS), progression-free survival (PFS), and recurrence pattern were also investigated. Sixty-nine patients were treated with chemoradiotherapy for germinoma, with a mean follow-up period of 108 months. Residual lesions were radiologically observed in 30 patients (43.5%). Among these, 5 patients (3 with pineal lesions and 2 with basal ganglia lesions) underwent salvage resection. Pathological examination revealed teratomatous components in 3 patients, whereas no tumoral components were identified in 2 patients. One patient with a basal ganglia lesion showed worsening of hemiparesis postoperatively. The remaining 25 patients received watchful observation without surgical intervention. Chronological periodic radiological change in residual lesions was evaluated in 21 patients. One year after primary treatment, the size of the residual lesions was stable and had decreased in 10 and 11 patients, respectively. None of the lesions increased in size. The 10-year PFS and OS rates were 96.7% and 97.3% in patients without residual lesions (n = 39), and 87.1% and 100% in patients with residual lesions (n = 30), respectively. Presence of residual lesions had no significant effect on PFS or OS. All recurrences occurred at distant sites or via dissemination without progression of the primary tumor site, regardless of the presence of residual lesion. End-of-treatment residual lesions are not rare in patients with germinoma, and these residual lesions seldom show progression. Because of the potential risk of surgical complications, the indication for early salvage surgery for residual lesions should be carefully determined. Watchful observation is recommended for the majority of these cases.


  • O12-4 Clinical significance of comprehensive genomic profiling in pediatric cancer patients

    by Minako Sugiyama, Junko Kikuchi, Yoshihito Ohhara, Kanako Hagio, Toraji Amano, Emi Takakuwa, C. Kanako Hatanaka, Yutaka Hatanaka, Atsushi Manabe, Takeo Sarashina, et al.

  • Open Access

    Central nervous system complications and white matter lesions by brain MRI in pediatric hematological malignancies

    by Minako Sugiyama, Shinsuke Hirabayashi, Yukayo Terashita, Yuko Cho, Akihiro Iguchi, Atsushi Manabe

    Several central nervous system complications in pediatric patients with hematological malignancies have been reported. We analyzed the frequency and the correlation with central nervous system involvement and intrathecal therapy. The frequency was 13 % (11/85), being almost equal to those in literature. We investigated high intensity areas, which indicated leukoencephalopathy, in the white matter by T2-weighted and/or fluid attenuated inversion recovery images (FLAIR) of the brain magnetic resonance imaging (MRI). Incidence of white matter lesions was higher in patients who received over 10 times of intrathecal therapy (p = 0.018). Patients who received repetitive intrathecal therapy should undergo close MRI to find out if they need cognitive functioning test. However, it may be possible to omit brain MRI in patients with acute myeloid leukemia and lymphoma who have received intrathecal therapies less than five times in a consideration of their burden in terms of sedation and cost.

  • Hepatoblastoma with bone/bone marrow metastasis in Li‐Fraumeni syndrome patient

    by Masataka Hasegawa, Minako Sugiyama, Yukayo Terashita, Yuko Cho, Atsushi Manabe


  • Notable therapeutic response in a patient with systemic juvenile xanthogranuloma with KIF5B‐ALK fusion

    by Minako Sugiyama, Shinsuke Hirabayashi, Yukitomo Ishi, Junko Kikuchi, Ayako Ishikura, Hiroaki Motegi, Yuki Ueda, Saori Sawai, Kazuya Hara, Yukayo Terashita, et al.


  • Open Access

    Refractory malignant hepatocellular tumor consisting of hepatocellular carcinoma and hepatoblastoma in a 10-year-old male

    by Minako Sugiyama, Shinsuke Hirabayashi, Yukayo Terashita, Yuko Cho, Akihiro Iguchi, Yoshihito Ohhara, Daisuke Abo, Shohei Honda, Emi Takakuwa, Atsushi Manabe

    Although hepatoblastoma constitutes most of hapetic tumours in chidren, other types of tumors are often observed in older patients. We report a case of a 10-year-old Japanese boy with a transitional hepatic tumour consisting of both hepatoblastoma and hepatocellular carcinoma. After surgery and chemotherapy with cisplatin and pirarubicin, the tumour regressed, however, new tumours in the liver evolved with element of hepatocellular carcinoma. He died as a result of hepatic failure afte lenvatinib and drug-eluting transcatheter arterial chemoembolisation 18 months after diagnosis. Examinations of a panel of genomic alterations did not identify any therapeutic targets.

  • 131I‐MIBG therapy with WT‐1 peptide for refractory neuroblastoma

    by Minako Sugiyama, Kinuya Seigo, Yosuke Hosoya, Akihiro Iguchi, Atsushi Manabe